Vitamin C clinical brief
Vitamin C
Dossier liveACompound
Evidence strength
High confidence
279 meta-analyses - 400 RCTs - 925 tracked studies
This page is grounded in structured dossier fields, with deterministic summaries layered on top for readability.
What it is for
General vitamin C adequacy and tissue store repletion
The clearest current human use case based on dose, outcomes, and clinical coverage.
What moves
Highest-signal biomarkers
Folate
Methylation
Decrease
Grade A
TC
Lipid response
Decrease
Grade A
hs-CRP
Inflammation
Decrease
Grade A
Top caution
Drug interaction
In the HATS trial, antioxidant combination (vitamin C 1000 mg + vitamin E 800 IU + beta-carotene + selenium) blunted the HDL2 benefit of simvastatin-niacin therapy.
Evidence index
86
Promoted product-registry confidence score
Meta-analyses
279
Pooled human evidence
RCTs
400
Randomized clinical trials
Tracked studies
925
Studies currently mapped to this dossier
Preview summary
Clinical opening brief
This executive summary is generated by application logic from structured dossier evidence and safety fields.
Vitamin C is a compound with its clearest current use in General vitamin C adequacy and tissue store repletion.
High confidence human evidence supports the brief, anchored by 925 tracked studies, 279 meta-analyses, 400 RCTs and the most reliable movement in Folate, TC, hs-CRP.
Vitamin C has an excellent safety profile at dietary and standard supplemental doses (<=500 mg/day). In the HATS trial, antioxidant combination (vitamin C 1000 mg + vitamin E 800 IU + beta-carotene + selenium) blunted the HDL2 benefit of simvastatin-niacin therapy.
Research unlocks the working sections of the brief
The clinical opening stays public. Research opens the deeper evidence, biomarker, dosing, and PGx layers once you want the full operating brief.
Evidence, biomarkers, dosing, and PGx stay behind the glass
You are already inside the dossier. Upgrade when you need the full working sections instead of only the opening memo.